The report, titled "Global HPV Vaccine Market" analyses the global market according to the type, disease indication, distribution channels, and region. The report offers thorough analysis of the market's historical and projected size along with trends analysis. Market share analysis and production capabilities of the most prominent companies, a summary of competition, strategic essentials, areas of potential growth, and analysis of competition for the players that are targeted within the global HPV market are highlighted in the report by RationalStat.

Market Overview and Dynamics: The growing incidence of HPV-related diseases drives the need for HPV vaccines

The global HPV vaccination market is expected to expand at a CAGR of 7% over the 2022-2028 forecast period. The efforts taken by governments around the world are likely to boost the need for HPV vaccines, as they concentrate on eliminating HPV-associated diseases. Additionally, strict government regulations will further boost the increasing demand for HPV vaccines in the upcoming years.

In addition, the increasing number of manufacturing companies are willing to help governmental organizations and to meet their demands which are expected to further increase the demand for HPV vaccines. Moreover, the initiatives of the government and actions taken by international health organizations such as "GAVI" are anticipated to provide a variety of possibilities for HPV vaccines over the upcoming years.

Furthermore, the increasing demand from the public is expected to increase in the few years owing to the increasing understanding and awareness of the global population. According to WHO, in Europe over 66,000 women have been diagnosed with cervical cancer. More than 30,000 die each year from cervical cancer. Due to this, various people have started getting jabbed with the HPV vaccine which is expected to fuel the demand for HPV vaccine.

Segmental Analysis

• Based on type, the 9-Valent Vaccine (Gardasil 9) segment is predicted to lead the market for the global HPV vaccine market due to the high demand for the 9-valent vaccine, which protects against nine HPV kinds (6 11-16, 18 31, 33, 45 52, 58, and) and aids in reducing the risk of HPV associated cancer.
• Based on the Disease Indication, Cervical cancer is predicted to dominate the sales of HPV vaccines, as increasing demand for HPV vaccines is growing since cervical cancer immunization is expected to witness growth in the forthcoming years.
• Based on Distribution Channel, Doctor offices/hospitals, and Retail pharmacies are expected to dominate in the market since hospitals are equipped with the equipment required for treatment and other related reasons.

  Competition Analysis: Regional Players Dominate the Domestic Markets

  Due to the presence of many well-established companies in the global HPV vaccine sector, there is intense competition. In order to preserve a competitive advantage in the market, the government has boosted its investment in HPV vaccines and is focusing on the complete eradication of HPV-associated cancers.  

  Acquisitions, product launches, and partnerships are the identified industry trend in the global HPV vaccine market. Significant consolidation is expected in the global market during the assessed period 2022-2028.

  • In September 2022, India’s indigenously developed cervical cancer vaccine (qHPV Vaccine) with the partnership between the Serum Institute of India (SII), the Department of Biotechnology (DBT), and the Biotechnology Industry Research Assistance Council (BIRAC).
  • In April 2022, Merck Co. announced the expansion of its vaccine manufacturing in Virginia to 120,000 square ft. to increase the capacity and supply of the HPV vaccine.

  Some of the prominent players operating in the global HPV vaccine market include Merck Co., GlaxoSmithKline plc, Serum Institute of India Pvt. Ltd., Johnson Johnson, AstraZeneca, Walvax Biotechnologies, Innovio Pharmaceuticals, Chengdu Institute of Biological Products Co., Ltd., Sanofi, and Shanghai Bowei among others.

  Among these, Merck Co. and GlaxoSmithKline plc are the prominent manufacturers and suppliers of the HPV vaccine.

  RationalStat has segmented the global HPV vaccine market on the basis of type, indication, distribution channel, and region

  • By Type
    • 9-Valent Vaccine
    • Quadrivalent Vaccine
    • Bivalent Vaccine
  • By Indication
    • Cervical Cancer
    • Genital Warts
    • Oropharyngeal Cancer
    • Vulvar Cancer
    • Penile Cancer
    • Vaginal Cancer
    • Anal Cancer
    • Others (Head Cancer, Neck Cancer, etc.)
  • By Distribution Channel
    • Doctor Offices / Hospitals
    • School-Based Health Centers
    • Government Suppliers
    • Retail Pharmacies
    • Online Pharmacies
  • By Region
    • North America
    • Latin America
    • Western Europe
    • Eastern Europe
    • Asia Pacific
    • Middle East Africa

   

   

  For more information about this report (link)

  About RationalStat LLC

  RationalStat is an end-to-end US-based market intelligence and consulting company that provides comprehensive market research reports along with customized strategy and consulting studies.  The company has sales offices in India, Mexico, and the US to support the middle east and diversified businesses. The company has over 80 consultants and industry experts, developing more than 850 market research and industry reports for its report store annually.

  RationalStat has strategic partnerships with leading data analytics and consumer research companies to cater to the client’s needs. Additional services offered by the company include consumer research, country reports, risk reports, procurement intelligence, data analytics, and analytical dashboards.

  Contact

  RationalStat LLC
  Kimberly Shaw, Content and Press Manager
  sales@rationalstat.com
  Phone: +1 302 803 5429